Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMGS-001 |
| Synonyms | |
| Therapy Description |
IMGS-001 is a monoclonal antibody that targets CD274 (PD-L1) and PDCD1LG2 (PD-L2), potentially leading to antibody-dependent cellular cytotoxicity and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMGS-001 | IMGS001|IMGS 001 | PD-L1 Inhibitor 15 | IMGS-001 is a monoclonal antibody that targets CD274 (PD-L1) and PDCD1LG2 (PD-L2), potentially leading to antibody-dependent cellular cytotoxicity and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |